[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allogenic-stem-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allogenic-stem-cell-transplantation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100651257","phase-1-allogeneic-inkt-cell-therapy-agent-797-after-sct-100651257",false,"NCT07758218","Allogeneic iNKT Cell Therapy (agenT-797) After SCT","UW26004: Phase I Trial of Allogeneic iNKT Cell Therapy (agenT-797) in Patients Undergoing Allogeneic Hematological Stem Cell Transplantation (SCT)","Inclusion Criteria:\n\n* Age ≥18 years at the time of consent\n* Adult patients anticipated to get an allogeneic hematopoietic cell transplantation (allo-SCT)\n* All donor types are accepted (MMUD \\[mismatched unrelated donor\\], MUD \\[matched unrelated donor\\], MSD \\[matched sibling donor\\], haploidentical)\n* All conditioning regimens will be accepted (MAC \\[myeloablative conditioning\\], RIC \\[reduced-intensity conditioning\\], NMAC \\[non-myeloablative conditioning\\])\n* Karnofsky Performance Scale (KPS) \\> 70\n* Eligible Diagnoses:\n\n  * Acute myeloid leukemia (AML) with intermediate\u002Fhigh-risk features or relapsed disease\n  * Chronic myeloid leukemia (CML) in accelerated or blast phases\n  * Myelodysplastic syndrome (MDS) with intermediate\u002Fhigh-risk features\n  * Acute lymphoblastic leukemia (ALL) with high-risk features or relapsed disease\n  * or any patients undergoing allogeneic stem cell transplant (allo-SCT) as standard of care could be eligible\n\nExclusion Criteria:\n\n* Excluded Diagnoses: Primary Myelofibrosis in the dose escalation phase and could be included in the dose-expansion phase","ALL","18 Years",{"count":19,"type":20},22,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The goal of this clinical trial is to learn if agenT-797 is safe to use on people undergoing allogenic hematological stem cell transplantation (SCT). The main questions it aims to answer are:\n\n* Is agenT-797 safe to use?\n* What medical problems do participants have when taking agenT-797?\n\nParticipants will receive an infusion of agenT-797 about 7 days after their allogenic SCT.",[26,27,28,29,30,31],"Allogenic Stem Cell Transplantation","Myeloid Malignancies","Lymphoid Malignancies","Acute Myeloid Leukemia","Chronic Myeloid Leukemia","Myelodysplastic Syndrome","NOT_YET_RECRUITING","2026-08-05",{"date":35,"type":36},"2026-08-11","ACTUAL",{"date":38,"type":20},"2026-10",{"date":40,"type":20},"2029-10",{"name":42,"class":43},"University of Wisconsin, Madison","OTHER"]